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Summary
 
PIR-A and PIR-B, paired immunoglobulin-like receptors encoded, respectively, by multiple
 
Pira
 
 genes and a single 
 
Pirb
 
 gene in mice, are relatives of the human natural killer (NK) and Fc
receptors. Monoclonal and polyclonal antibodies produced against a recombinant PIR protein
identified cell surface glycoproteins of 
 
z
 
85 and 
 
z
 
120 kD on B cells, granulocytes, and mac-
rophages. A disulfide-linked homodimer associated with the cell surface PIR molecules was
identified as the Fc receptor common 
 
g
 
 (FcR
 
g
 
c) chain. Whereas PIR-B fibroblast transfectants
expressed cell surface molecules of 
 
z
 
120 kD, PIR-A transfectants expressed the 
 
z
 
85-kD mol-
ecules exclusively intracellularly; PIR-A and FcR
 
g
 
c cotransfectants expressed the PIR-A/
FcR
 
g
 
c complex on their cell surface. Correspondingly, PIR-B was normally expressed on the
cell surface of splenocytes from FcR
 
g
 
c
 
2
 
/
 
2
 
 mice whereas PIR-A was not. Cell surface levels of
PIR molecules on myeloid and B lineage cells increased with cellular differentiation and activa-
tion. Dendritic cells, monocytes/macrophages, and mast cells expressed the PIR molecules in
varying levels, but T cells and NK cells did not. These experiments define the coordinate cellu-
lar expression of PIR-B, an inhibitory receptor, and PIR-A, an activating receptor; demon-
strate the requirement of FcR
 
g
 
c chain association for cell surface PIR-A expression; and sug-
gest that the level of FcR
 
g
 
c chain expression could differentially affect the PIR-A/PIR-B
equilibrium in different cell lineages.
Key words: Fc receptor 
 
g
 
 chain • activating receptor • inhibitory receptor • dendritic cells • 
innate immunity
 
T
 
he paired immunoglobulin-like receptors (PIR)
 
1
 
-A
and -B have been identified recently in mice on the
basis of their homology with the human Fc
 
a
 
 receptor
(Fc
 
a
 
R) (1, 2). PIR-A and PIR-B share sequence similarity
with a gene family that includes human Fc
 
a
 
R and killer in-
hibitory receptors (KIR), mouse gp49, bovine Fc receptor
for IgG (Fc
 
g
 
R), and the recently identified human Ig-like
transcripts (ILT)/leukocyte Ig-like receptors (LIR)/mono-
cyte/macrophage Ig-like receptors (MIR) (3–12). The 
 
Pira
 
and 
 
Pirb
 
 genes are located on mouse chromosome 7 in a re-
gion syntenic with the human chromosome 19q13 region
that contains the 
 
Fc
 
a
 
R
 
, 
 
KIR
 
, and 
 
ILT
 
/
 
LIR
 
/
 
MIR
 
 genes (1,
4, 5, 9, 11–14). DNA sequences for PIR-A and PIR-B
predict type I transmembrane proteins with similar ecto-
domains (
 
.
 
92% homology) each containing six Ig-like
domains. However, PIR-A and PIR-B have distinctive
membrane proximal, transmembrane, and cytoplasmic re-
gions. The PIR-B protein, encoded by the 
 
Pirb
 
 gene (1,
13, 15), has a typical uncharged transmembrane region and
a long cytoplasmic tail with multiple candidate immunore-
ceptor tyrosine–based inhibitory motifs (ITIMs). Recent
studies have demonstrated the inhibitory function of the
two most membrane-distal ITIM units in the PIR-B cyto-
 
H. Kubagawa and C.-C. Chen contributed equally to this work.
 
1
 
Abbreviations used in this paper:
 
 CY, cychrome; EC, extracellular domain;
Fc
 
a
 
R, Fc receptor for IgA; Fc
 
g
 
R, Fc receptor for IgG; FcR
 
g
 
c, Fc recep-
tor common 
 
g
 
 chain; ILT, Ig-like transcript; ITAM, immunoreceptor ty-
rosine–based activation motif; ITIM, immunoreceptor tyrosine–based in-
hibitory motif; KIR, killer inhibitory receptor; LIR, leukocyte Ig-like
receptor; MIR, monocyte/macrophage Ig-like receptor; PIR, paired Ig-
like receptor; SPIT, solid-phase immunoisolation technique. 
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plasmic region (16, 17). The PIR-B inhibitory function is
mediated through ITIM recruitment of the protein ty-
rosine phosphatase SHP-1 (16, 17). Conversely, the pre-
dicted PIR-A protein has a short cytoplasmic tail and a
charged arginine residue in its transmembrane region, sug-
gesting possible association with transmembrane proteins
containing immunoreceptor tyrosine–based activation mo-
tifs (ITAMs) to form a signal-transducing unit. In addition,
the PIR-A receptors, which are encoded by multiple 
 
Pira
 
genes, display sequence diversity in their extracellular re-
gions.
In this study, monoclonal and polyclonal antibodies spe-
cific for common epitopes on PIR-A and PIR-B mole-
cules were used to characterize these cell surface receptors
and the cellular distribution of their expression in normal
and Fc receptor common 
 
g
 
 chain (FcR
 
g
 
c)–deficient mice.
The results indicate an essential role for PIR-A association
with the FcR
 
g
 
c for cell surface expression on B lineage,
myeloid, and dendritic cells.
 
Materials and Methods
 
Cell Preparation.
 
Bone marrow cells were isolated from the
femur by flushing with media, and the erythrocytes lysed in a 0.1 M
ammonium chloride buffer solution at pH 7.4. Splenocytes were
prepared by splenic disruption, gentle teasing, and density gradi-
ent centrifugation over Lympholyte
 
®
 
-M (Accurate Chemistry &
Science Corp.). Splenic B cells were enriched by depletion of
Mac-1
 
1
 
 macrophages and granulocytes and of CD3
 
1
 
 T cells by a
panning method (18). Granulocytes were isolated from peritoneal
exudates induced by prior injection of 0.4% (wt/vol) calcium
caseinate (Spectrum Quality Products, Inc.).
 
Preparation of Recombinant PIR Protein.
 
The PIR extracellular
domains EC1 and EC2 were amplified by PCR using 
 
Taq
 
 DNA
polymerase and the PIR-A1 cDNA as the template. The for-
ward primer, 5
 
9
 
-GCACGGATCCCTCCCTAAGCCTATCCT-
CAGA-3
 
9
 
, corresponds with the 5
 
9
 
 side of the EC1 (the BamHI
site is underlined), and the reverse primer 5
 
9
 
-TATCGATAAG-
CTTGAGACCAGGAGCTCCA-3
 
9
 
, with the 3
 
9
 
 side of the
EC2 (the HindIII site being underlined). The 
 
z
 
570-bp pro-
ducts were purified by agarose gel electrophoresis, digested with
BamHI and HindIII, and ligated into the pQE30 expression vec-
tor (Qiagen) which was used to transform 
 
Escherichia coli
 
, strain
M15. The His-tagged PIR-A1 EC1/EC2 protein produced by
transformed M15 cells after induction with 1 mM isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside was purified on an affinity column
(Ni-nitrilo-tri-acetic acid resin; Qiagen), eluted with 8 M urea/0.1
M acetate buffer, pH 4.5, and renatured by dialysis against PBS.
 
Production of Monoclonal and Polyclonal Antibodies.
 
Lewis rats were
immunized five times at weekly intervals with 50 
 
m
 
g of purified
PIR-A1 EC1/EC2 protein. The rats were then boosted with the
WEHI3 myeloid cell line (10
 
7
 
 cells), which expresses PIR-A and
PIR-B transcripts (1), a day before fusion of regional lymph node
cells with the Ig nonproducing murine plasmacytoma cell line
(Ag8.653) (19). Hybridoma culture supernatants were screened
for reactivity with the recombinant protein by ELISA using
alkaline phosphatase–labeled goat antibodies specific for rat Ig
(Southern Biotechnology Associates). ELISA reactive super-
natants were examined for immunofluorescence cell surface re-
activity with the PIR
 
1
 
 WEHI3 and PIR
 
2
 
 M1 cell lines using
PE-labeled goat antibodies specific for rat Ig. Selected hybridoma
 
clones were subcloned by limiting dilution in the presence of
rIL-6 (1 U/ml; GIBCO BRL). Ig isotypes of the mAbs were de-
termined with a rat mAb ELISA kit (Zymed Co.). Anti-PIR
mAbs purified from culture supernatants by protein-G affinity
columns were labeled with PE or biotin. A New Zealand White
rabbit was hyperimmunized with the recombinant PIR-A1 EC1/
EC2 protein (50 
 
m
 
g, six times) over a 2-mo period, and the anti-
serum collected 10 d after the final immunization.
 
Transfection.
 
Expression vectors were constructed by digest-
ing the original PIR-A1 and PIR-B cDNAs in the Bluescript
phagemid vector with XbaI, filling the recessed 3
 
9
 
 termini with
Klenow fragment, redigesting with XhoI, and separation by aga-
rose gel electrophoresis. The separated XbaI (blunt ended)/XhoI
fragments, 
 
z
 
3.4 kb for PIR-A1 and 
 
z
 
2.7 kb for PIR-B, were
excised, purified, and ligated into the pcDNA3 expression vector
that was predigested with EcoRV and XhoI and dephosphory-
lated with calf intestinal alkaline phosphatase to construct
pcDNA3-PIR-A1 and pcDNA3-PIR-B. Since both PIR-A1
and PIR-B cDNAs contained additional ATG sites located up-
stream of the initiation codon, the 5
 
9
 
 untranslated regions were
removed and replaced by Kozak sequence (20). This was accom-
plished by 67mer complementary oligonucleotides: the forward
5
 
9
 
-
 
AGCT
 
TGCCGCCACC
 
ATGTCCTGCACCTTCACAG
 
-
 
CCCTGCTCCGTCTTGGACTGACTCTGAGCCTCTG
 
-3
 
9
 
and the reverse 5
 
9
 
-
 
GATC
 
CAGAGGCTCAGAGTCAGTC
 
-
 
CAAGACGGAGCAGGGCTGTGAAGGTGCAGGACAT
 
-
GGTGGCGGCA-3
 
9
 
; italic, underlined, and bold letters corre-
spond with the cohesive ends of HindIII or BamHI, the Kozak
sequence, and the signal sequence of both PIR-A1 and PIR-B
cDNAs, respectively. The 5
 
9
 
-hydroxyl termini of both oligonu-
cleotides were phosphorylated by T4 polynucleotide kinase, an-
nealed, and ligated into the pcDNA3-PIR-A1 and pcDNA3-
PIR-B expression vectors, from which the 100–200-bp HindIII/
BamHI fragments corresponding with the 5
 
9
 
 untranslated region
and a part of the signal sequence of PIR-A1 and PIR-B cDNAs
had been excised. After confirming the nucleotide sequences of
the resultant PIR-A1 and PIR-B expression vectors, the plasmid
DNAs were linearized by digesting with PvuI, transfected into
LTK fibroblasts with the aid of lipofectin, and stable transfectants
selected by Geneticin (G418) exposure.
For cotransfection of a murine FcR
 
g
 
c into the PIR-A1–trans-
fected fibroblasts, the FcR
 
g
 
c expression vector was constructed
by ligating the 
 
z
 
400-bp FcR
 
g
 
c coding sequence from the origi-
nal pcEXV-3 vector (21) into EcoRI-digested pBluescript II
cloning vector. The pBlue-FcR
 
g
 
c construct with a correct ori-
entation was digested with BamHI and XhoI to remove the
FcR
 
g
 
c fragment, before ligation into the pcDNA3.1/Hygro(
 
1
 
)
expression vector. The resulting expression vector pcDNA3.1/
Hygro-FcR
 
g
 
c was then linearized with AviII and transfected
with the aid of Superfect into LTK fibroblasts which had been al-
ready transfected with PIR-A1. Stable cotransfectants were se-
lected by Geneticin (G418) and Hygromycin B.
 
Western Blot Analysis.
 
B cells and myeloid cells (5 
 
3
 
 10
 
7
 
cells/sample) and PIR-A or PIR-B transfected LTK cells (10
 
6
 
)
were lysed in 500 
 
m
 
l of lysis buffer (1% NP-40 in 150 mM NaCl/
50 mM Tris-HCl, pH 7.5, containing 5 mM EDTA, 20 mM io-
doacetamide, 0.1% sodium azide, 20 mM 
 
e
 
-amino-caproic acid,
antipain [2 
 
m
 
g/ml], leupeptin [1 
 
m
 
g/ml], soybean trypsin inhibi-
tor [100 
 
m
 
g/ml], aprotinin [2 
 
m
 
g/ml], 1 mM 4-(2-aminoethyl)-
benzenesulfonyl fluoride hydrochloride, chymostatin [2.5 
 
m
 
g/ml],
and pepstatin [1 mg/ml]). A solid-phase immunoisolation tech-
nique (SPIT) (22) was used to identify anti-PIR reactive mole-
cules in cell lysates precleared by centrifugation. In brief, 96-well311 Kubagawa et al.
Figure 1. Cell surface reactivity
of the 6C1 anti-PIR mAb. Mouse
LTK cells transfected with the
empty vector (A), LTK cells trans-
fected with the PIR-B expression
vector (B), M1 myeloblastoid cells
(C), and WEHI3 myeloid cells
(D) were incubated with 6C1 rat
anti-PIR mAb (shaded histogram)
or an isotype-matched control
mAb (open histogram), before de-
veloping with PE-labeled goat an-
tibodies to rat Ig. The stained cells
were analyzed by flow cytometry.
plates were coated with goat antibodies to rat Ig and then with rat
anti-PIR or isotype-matched control mAbs before incubation
with cell lysates overnight at 48C. After extensive washing,
bound molecules were dissociated by addition of 2% SDS, re-
solved by SDS-PAGE, transferred onto nitrocellulose membranes
by electroblotting, incubated sequentially with rabbit anti-PIR
antiserum (1:2,000 dilution) and horseradish peroxidase–labeled
goat anti–rabbit Ig antibody (0.25 mg/ml; Southern Biotechnol-
ogy Associates), and visualized by enhanced chemiluminescence
(Amersham Life Science). In other experiments, blotted mem-
branes were incubated with rabbit antibodies against FcRgc (gift
of Drs. Robert P. Kimberly and Jeffery C. Edberg, University of
Alabama at Birmingham, Birmingham, AL).
Immunoprecipitation of Cell Surface Proteins. Viable cells (z3 3
107) were surface labeled with 1 mCi of Na125I by the lactoper-
oxidase method (23) and solubilized in z500 ml of 1% NP-40 or
1% digitonin lysis buffers. After centrifugation, iodinated PIR
molecules were isolated by SPIT, separated on SDS-PAGE (8–15%
acrylamide) under reducing and nonreducing conditions, and the
dried gels exposed to x-ray films (24). Alternatively, isolated PIR
molecules were analyzed by nonreducing/reducing diagonal
SDS-PAGE (25). In other experiments, cell surface PIR mole-
cules were digested with N-glycanase (Oxford Glycosciences) be-
fore SDS-PAGE analysis (24).
Immunofluorescence Analysis. Cells were incubated with aggre-
gated human IgG to block FcgRs, then stained with PE-labeled
anti-PIR mAbs and a combination of FITC-, cychrome (CY)-,
allophycocyanin, or biotin-labeled mAbs specific for B220
(CD45R), CD19, CD21, CD23, CD43, or CD5 for B-lineage
cells; CD3, CD4, or CD8 for T-lineage cells; Mac-1 (CD11b) or
Gr-1 for myeloid lineage cells; DX5 antigen for pan NK cells;
CD11c for dendritic cells; and Ter-119 for erythroid lineage cells
(PharMingen). Other reagents included FITC-labeled goat anti–
mouse m chain antibody and isotype-matched control mAbs la-
Figure 2. Analysis of cell surface and intracellular PIR molecules. Viable splenocytes from normal adult BALB/c mice were radiolabeled with 125I and
solubilized in 0.5% NP-40. The cleared membrane lysates were incubated in wells precoated with 6C1 anti-PIR or an isotype-matched control mAb.
The bound materials were resolved on SDS-PAGE using 10% acrylamide under nonreducing (not shown) and reducing conditions (A) or digested with
or without N-glycanase before SDS-PAGE analysis (B). The same z85 and z125-kD PIR molecules were observed in splenocytes, purified splenic B
cells, and granulocytes (C) as well as the X16C8.5 B cell and WEHI3 macrophage cell lines (D). In contrast, the 85-kD band was identified in PIR-A
transfected fibroblasts, while the z120-kD band was expressed by the PIR-B transfectants (D). In the experiments shown in C and D, NP-40 lysates of
splenocytes, purified B cells, granulocytes, the LTK cells transfected with empty vector or PIR-A1 or PIR-B expression vectors, the X16C8.5 B cell line,
and the WEHI3 macrophage cell line were incubated in wells precoated with 6C1 anti-PIR mAb or isotype-matched control mAb (not shown). The
bound PIR molecules were separated in SDS-PAGE under nonreducing conditions, transferred onto membranes, and identified with rabbit anti-PIR an-
tiserum and enzyme-labeled goat anti–rabbit Ig antibody before visualization by enhanced chemiluminescence.312 Paired Immunoglobulin-like Receptors
beled with PE, FITC, CY, or biotin (Southern Biotechnological
Associates). Stained cells were analyzed with a FACScan® flow
cytometry instrument (Becton Dickinson).
Results
Generation of Monoclonal and Polyclonal Anti-PIR Antibod-
ies. Recombinant PIR protein containing the two NH2-
terminal Ig-like extracellular domains, EC1 and EC2, in
the PIR-A1 molecule was produced in E. coli. The PIR-
A1 EC1/EC2 recombinant protein was selected to immu-
nize rats because of its sequence identity with PIR-B (1). 1 d
before fusion of regional lymph node cells to produce
hybridomas, the immunized rats were boosted with viable
WEHI3 myeloid cells to enhance the possibility of obtaining
antibodies that recognize epitopes on native PIR molecules.
33 hybridoma clones produced antibodies that reacted by
ELISA with the recombinant PIR-A1 EC1/EC2 protein.
Cell surface immunofluorescence analysis indicated that one
of the antibodies, 6C1 (g1k), was reactive with PIR-B–trans-
fected LTK fibroblasts and the WEHI3 myeloid cell line
(Fig. 1). This mAb was unreactive with mock-transfected
LTK fibroblasts and the M1 myeloblastoid cell line that lack
PIR-A and PIR-B transcripts. Binding of the 6C1 anti-
body to the WEHI3 cells was inhibited by the recombinant
PIR-A1 EC1/EC2 protein in a dose-dependent manner.
The recombinant PIR-A1 EC1/EC2 protein was also used
to produce a rabbit antiserum, the specificity of which was
indicated by ELISA and by Western blot assays of the native
PIR-A and PIR-B proteins described below.
Biochemical Characteristics of the PIR-A and PIR-B Mole-
cules. When iodinated cell surface proteins on spleno-
cytes, B cell lines, and macrophage cell lines were exam-
ined by SDS-PAGE, the anti-PIR antibodies identified
two major species of z85 and z120 kD with minor bands
of slightly lower molecular masses (Fig. 2 A). Slightly
higher molecular masses were evident under reducing con-
ditions, z90 and z125 kD, respectively, consistent with
predicted intradisulfide linkages of the six Ig-like extracel-
lular domains. N-glycanase treatment reduced their appar-
ent molecular masses by 10–15 kD in keeping with the
presence of five to six potential N-linked glycosylation sites
in the PIR-A and PIR-B molecules (Fig. 2 B). Two-
dimensional electrophoretic analysis under nonreducing and
reducing conditions confirmed that the z85 and z120-kD
proteins identified on splenocytes by the anti-PIR antibod-
ies did not exist as covalently linked molecules (not
shown). B cells purified from the spleen and granulocytes
purified from peritoneal exudates also expressed z85 and
z125-kD molecules (Fig. 2 C). These findings indicate
that cell surface PIR molecules are glycoproteins of z85
and  z120 kD, and that both molecular species are ex-
pressed by clonal B and myeloid cells.
Since the monoclonal and polyclonal antibodies recog-
nize epitopes present on both PIR-A and PIR-B mole-
cules, mouse LTK cells transfected either with PIR-A1 or
PIR-B cDNAs were used for discrimination of the PIR
molecules. A major band of z120 kD, together with a faint
band of z97 kD, was immunoprecipitated by the 6C1
anti-PIR mAb from lysates of the PIR-B transfectants, and
not from lysates of mock transfectants probed by immuno-
blotting with the rabbit anti-PIR antibodies (Fig. 2 C).
Conversely, the anti-PIR mAb precipitated a major band
of z85 kD and a minor band of z70 kD from cell lysates
of the PIR-A1 transfectants. The two major bands of 85
and 120 kD were also identified by the 6C1 mAbs and the
rabbit anti-PIR antibodies in normal splenocytes, B cell,
and myeloid cell lines, all of which express Pira and Pirb
Figure 3. Association of PIR-A with FcRgc. (A) Assessment of cell sur-
face PIR-A expression on LTK fibroblasts transfected with PIR-A alone
(left) or with PIR-A and FcRgc (right). Viable cells were incubated with
fluorochrome-labeled 6C1 anti-PIR (shaded histogram) or isotype-matched
control mAb (open histogram). (B) Assessment of PIR expression in FcRgc-
deficient versus normal mice. Splenocytes from FcRgc-deficient (FcRgc2/2)
or normal (FcRgc1/1) mice were either radiolabeled with 125I (top) or un-
labeled (middle and bottom), lysed in 1% NP-40, and subjected to immu-
noprecipitation (IP) with the indicated mAbs. The immunoprecipitated, ra-
diolabeled materials were resolved by SDS-PAGE and autoradiography
(top). The materials isolated from unlabeled cells were resolved by SDS-
PAGE, transferred onto membranes, blotted with rabbit anti-PIR (middle)
or anti-FcRgc antibodies (bottom), and visualized by chemiluminescence.313 Kubagawa et al.
transcripts (1). The 6C1 anti-PIR mAb and the rabbit anti-
serum against recombinant PIR EC1/EC2 protein thus
recognize native PIR-A and PIR-B molecules, the major
species of which have relative molecular masses of z85 and
z120 kD, respectively.
PIR-A Association with FcRgc. The PIR-A protein has
a short cytoplasmic tail without recognizable functional
motifs, but the presence of a charged amino acid, arginine,
in the transmembrane region suggested its potential associa-
tion with another transmembrane protein (1). Inferential
evidence in support of this possibility was provided by
studies of the cell surface proteins expressed by PIR-A and
PIR-B fibroblast transfectants. A major band of z120 kD
was identified on the cell surface of PIR-B transfected LTK
cells by the 6C1 antibodies (not shown), whereas the z85
and z70-kD molecules expressed by PIR-A1 transfectants
(see Fig. 2 C) were identified only intracellularly. Cell sur-
face PIR-A molecules were not identified by the anti-PIR
mAb on PIR-A transfectants, thereby implying that PIR-A
requires companion molecules, not present in fibroblasts, to
reach the cell surface. Accordingly, two-dimensional analy-
sis of the proteins precipitated with the 6C1 anti-PIR anti-
body from iodinated cell surface proteins on splenocytes
revealed an associated homodimer composed of relatively
small disulfide-linked subunits (z10 kD, not shown). Im-
munoblots of the cell surface PIR complex separated under
reducing conditions by SDS-PAGE identified these associ-
ated proteins as FcRgc (Fig. 3 B).
The requirement of FcRgc association for the cell sur-
face expression of PIR-A was examined by fibroblast
cotransfection experiments. While PIR-A producing trans-
fectants failed to express this product on the cell surface, fi-
broblasts cotransfected with the PIR-A and FcRgc con-
structs expressed readily detectable PIR-A on the cell
surface (Fig. 3 A). The apparent requirement of FcRgc for
cell surface expression of PIR-A molecules was examined
further by the analysis of FcRgc chain–deficient (FcRgc2/2)
mice. While splenocytes from the wild-type mice ex-
pressed both PIR-A and PIR-B on the cell surface, only
the PIR-B was identified on the cell surface of splenocytes
in FcRgc2/2 mice (Fig. 3 B). This selective impairment of
PIR-A cell surface expression in FcRgc2/2 mice was not
attributable to a lack of PIR-A production, since the 6C1
mAb identified both the 85-kD PIR-A and the 120-kD
PIR-B molecules within FcRgc2/2 splenocytes. There-
fore, these findings indicate that FcRgc chains are required
for the cell surface expression of PIR-A molecules.
Immunofluorescence Analysis of the Cellular Distribution of
PIR Expression. When bone marrow cells from adult
mice were incubated with the fluorochrome-labeled 6C1
anti-PIR mAb, z80% of the nucleated cells were stained.
Morphological analysis of isolated PIR1 cells indicated that
most were myeloid cells, ranging from immature myelo-
blasts to mature granulocytes, whereas lymphocytes repre-
sented a minor constituent. When differential immunoflu-
orescence analysis for other cell surface differentiation
antigens was conducted to further characterize the PIR1
cells, bone marrow cells bearing the Gr-1 and Mac-1
(CD11b, CR3) myelomonocytoid antigens were found to
express the PIR antigen at variable levels that correlated with
Gr-1 expression levels (Fig. 4, first row). Examination of the
morphological features of isolated PIRlo/Gr-1lo and PIRhi/
Gr-1hi fractions confirmed the increase in PIR and Gr-1 ex-
Figure 4. Immunofluorescence analysis of cell surface PIR expression.
Bone marrow (BM), spleen (SP), and peritoneal lavage (PEC) cells from
adult BALB/c mice were incubated first with aggregated human IgG to
block FcgR, then stained with a combination of PE-labeled 6C1 anti-PIR
and FITC-, CY-, allophycocyanin-, or biotin-labeled (and CY-labeled
streptavidin) mAbs with the following specificity: Mac-1 and Gr-1 for my-
eloid lineage cells (first row); CD43 and B220 antigens for pro-B/pre-B cell
compartment (second row); CD19 and IgM for B lineage cells (third row);
CD3 and DX5 for T and NK cells and CD19 or Mac-1 for B cells and
macrophages (fourth row); B220, CD21, and CD23 for marginal zone
(MZ), follicular (FO), and newly formed (NF) B cells (fifth row); CD19,
CD5, and Mac-1 for B1 and B2 subpopulations (sixth row). Staining of
cells with light scatter characteristics of myeloid cells or small lymphoid and
larger mononuclear cells was analyzed by flow cytometry. In the bottom
two rows, B2201 or CD191 B cells were examined for expression of the
indicated cell surface antigens. The cell populations indicated by boxes in
contour plots were examined for their expression of PIR molecules (solid
line) versus background staining with an isotype-matched control mAb
(dashed line). MFI indicates mean fluorescence intensity.314 Paired Immunoglobulin-like Receptors
pression with progression of granulocyte differentiation. The
B-lineage cells in bone marrow expressed PIR at lower lev-
els relative to the myeloid cells, and most of the PIR1 B-lin-
eage cells (CD191) were IgM1 B cells; pro-B were PIR
negative while pre-B cells were found to express PIR at low
levels (Fig. 4, second and third rows), indicating a gradual in-
crease in PIR expression as a function of B-lineage differ-
entiation. Bone marrow–derived, IL-3–induced mast cells
(c-kit1) also expressed PIR on their cell surface. PIR pro-
teins were not detected on erythroid lineage cells (Ter1191)
in the bone marrow. CD31 thymocytes from newborn and
adult BALB/c mice were PIR negative. In striking contrast,
thymic dendritic cells (MHC class II1, CD11c1, CD81,
CD32, CD42, CD192, Mac-12, FcgRII/III2) expressed PIR
from relatively low to high levels (Fig. 5).
Splenic B cells and macrophages expressed the PIR anti-
gen on their cell surface, whereas NK cells and T cells did
not (Fig. 4, fourth row), results consistent with the expres-
sion patterns noted for PIR-A and PIR-B transcripts in
these cell types (1). PIR expression was higher on myeloid
lineage cells than on splenic B cells, the latter bearing the
6C1-identified PIR molecules in highly variable levels.
When subpopulations of splenic B cells were evaluated, the
marginal zone B cells (B2201, CD21high, CD23low/2) were
found to express higher PIR levels than newly formed
(B2201, CD212, CD232) and follicular B cells (B2201,
CD21med, CD231) (Fig. 4, fifth row). Moreover, the B1
subpopulations of B cells in peritoneal lavage expressed
higher levels of PIR than did the B2 cells (Fig. 4, sixth
row). Consistent with this suggestive evidence that B cell
activation may enhance PIR expression, cell surface levels
of PIR were upregulated by z33% after LPS stimulation
of splenic B cells, and macrophage PIR expression was
similarly enhanced by LPS stimulation. Splenic dendritic
cells (MHC class II1, CD11c1, CD192, Mac-12, CD81/2,
FcgRII/III2), like thymic dendritic cells, were found to ex-
press relatively low to relatively high levels of PIR (Fig. 5).
Cell Surface Expression Levels of PIR-B in FcRgc2/2
mice. Since cell surface expression of PIR-A was selec-
tively impaired in FcRgc-deficient mice, PIR-B expres-
sion relative to total PIR-A/PIR-B expression could be es-
timated by immunofluorescence comparison of the cells
from FcRgc-deficient and wild-type mice. Cell surface
PIR-B expression alone was thereby found to increase in
the FcRgc-deficient mice as a function of both myeloid
and B lineage differentiation (Fig. 6).
Discussion
The monoclonal and polyclonal anti-PIR-A/PIR-B an-
tibodies described here define the cell surface PIR-A and
PIR-B receptors as glycoproteins of z85 and z120 kD,
respectively. The z120-kD estimate for PIR-B agrees
with that obtained using a rabbit antiserum against a p91/
PIR-B cytoplasmic peptide (2). In the present studies, the
coordinate or paired expression of PIR-A and PIR-B by B
and myeloid cells suggested by transcriptional analysis (1)
was confirmed by demonstration of both molecules on rep-
resentative clonal cell lines. Given the finding of splice
variants among PIR-A cDNAs (1), we anticipated consid-
erable size heterogeneity of the PIR-A proteins. Contrary
to this expectation, the cell surface PIR-A and PIR-B re-
ceptors were relatively homogeneous in size, and the pre-
dominant protein species were physically indistinguishable
in different cell types (B cells versus macrophages) and cell
sources (cell lines versus splenocytes). The products of
splice variant PIR-A cDNAs thus appear to comprise only
a minor fraction of the total PIR-A pool. The PIR-A and
PIR-B cDNA sequences indicate an additional free Cys resi-
due in their ectodomains (1), thus suggesting the possible ex-
istence of disulfide-linked dimers of the PIR-A and PIR-B
molecules. However, disulfide linkage of these molecules
was not evident in either one- or two-dimensional gel elec-
trophoresis analyses. It is still theoretically possible that cell
surface PIR-A and PIR-B molecules could form noncova-
lent associations with functional consequence.
Intriguingly, the anti-PIR mAb recognized the PIR-B
cell surface receptor on PIR-B transfectants, whereas PIR-A
cell surface molecules could not be detected on PIR-A1
producing transfectants. This finding implied the require-
Figure 5. PIR expression by
thymic and splenic dendritic
cells. (Top) Thy-11 T and
B2201 B cells were depleted
from thymic cell suspensions by
complement-mediated lysis, and
the remaining cells were stained
with the indicated mAbs. The
CD11c1/CD192 cells, which
comprised  z1% of the initial
MNC population, were analyzed
for the expression of PIR and
other cell surface markers (MHC
I-Ad, Mac-1, CD8, and FcgRII/
III). (Bottom) Splenocytes were
stained similarly, and the
CD11c1/CD192 cells analyzed
for other cell surface antigens.315 Kubagawa et al.
ment for additional membrane-bound protein(s) for PIR-A
cell surface expression, a possibility that was also suggested
by the presence of a charged Arg residue in the transmem-
brane region of the predicted PIR-A1 protein (1). There
are well documented precedents for the noncovalent asso-
ciation of Ig-like receptor chains containing such charged
transmembrane regions with another membrane-bound
protein for cell surface expression and/or function. These
include (a) the association of ligand-binding a chain of sev-
eral Fc receptors (FceR, FcgRI, FcgRIII, FcaR) with sig-
nal transducing subunits (b, g, or z); (b) the TCR/CD3
complexes; and (c) the killer activating receptor/dendritic
associated protein-12 or killer activating receptor associat-
ing protein complexes (20, 26–38). In these examples, the
associated proteins typically contain ITAMs in their cyto-
plasmic domains (31, 39–42). Our immunoprecipitation
analysis indicated that the ITAM-containing FcRgc is asso-
ciated with PIR molecules present on the cell surface. The
implication that the FcRgc is essential for PIR-A cell sur-
face expression was confirmed in fibroblast cotransfection
studies and by the selective expression of PIR-B molecules
on B cells and myeloid cells in FcRgc-deficient mice. In
studies reported since submission of this manuscript, a cell
activation for the PIR-A/FcRgc complex has been dem-
onstrated in rat mast cell line and chicken B cell line trans-
fected with constructs for chimeric proteins containing the
PIR-A transmembrane and cytoplasmic regions (43, 44).
The restricted expression of PIR molecules by B and
myeloid lineage cells indicated by our immunofluorescence
analysis is consistent with previous analyses of PIR-A and
PIR-B transcripts (1, 2). Cell surface PIR expression was
found to increase as a function of cellular differentiation in
both cell lineages, indicating that the PIR family is prima-
rily involved in mature cell function. The levels of PIR-A/
PIR-B expression by splenic B cells were remarkably vari-
able. Examination of the different splenic subpopulations
indicated that the expression levels were highest on mar-
ginal zone B cells, which appear to be primed cells (45).
Correspondingly, the B1 subpopulations of B cells ex-
pressed higher PIR levels than did the B2 subpopulation.
The suggestion that activated B cells may express higher
PIR levels was supported by the observation that LPS stim-
ulation enhanced B cell and myeloid cell expression of the
PIR molecules, in keeping with the presence of potential
binding sites for the LPS– or IL-6–dependent DNA-bind-
ing protein in the promoter region of the Pirb gene (15).
In addition to B cells and myeloid lineage cells, the den-
dritic cells in the thymus and spleen, defined as MHC class
II1 CD11c1 CD81/2 CD42 CD192 Mac-12, were also
found to express the PIR molecules on their surface. This
finding suggests that the variable PIR-A molecules and in-
variant PIR-B molecules could be involved in self/non-self
discrimination or antigen presentation. The human Ig-like
ILT/LIR/MIR receptors, which share 50–60% sequence
similarity with mouse PIR, are also expressed by B cells,
monocyte/macrophages, and dendritic cells, but, unlike the
murine PIR molecules, these human relatives may also be
expressed by NK cells and a subpopulation of T cells (9, 11,
46). Some members of the human ILT/LIR/MIR family
have been shown to bind classical or nonclassical MHC
class I alleles (10, 46–48). Although the ligand or ligands for
the PIR molecules are presently unknown, their pattern of
expression on myeloid, lymphoid, and dendritic cells sug-
gests that, like other Ig-like cell surface receptors, they may
coligate with other activation/inhibitory systems to modu-
late inflammatory and immune responses. In this regard,
these results suggest that the PIR-A requirement for FcRgc
association could result in differential regulation of the
PIR-A/PIR-B equilibrium as a function of cellular activa-
tion or differentiation pathway.
Figure 6. PIR expression in FcRgc-deficient and wild-type mice.
Bone marrow cells from FcRgc-deficient (thick line) and wild type mice
(thin line) were stained with 6C1 anti-PIR or control (dotted line) mAb,
and the stained cells were analyzed as described in the legend for Fig. 4.
Only the wild-type mice control staining is illustrated.316 Paired Immunoglobulin-like Receptors
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